|
In a key clinical study recently published in
Osteoporosis International, Demetech AB, Stockholm, has clearly
demonstrated that their proprietary DXL technology and heel
measurement can be used applying WHO criteria for diagnosis of
osteoporosis. This will dramatically simplify the diagnosis of
osteoporosis in primary care.
The lifetime prevalence for osteoporosis is more than 30% for women
and 13% for men. In order to combat this disease and its severe
consequences for those affected, WHO, issued diagnostic guidelines
in 1994. Several initiatives on governmental level are currently
driven in the USA and in the EU to raise awareness and improve
patient care.
Lack of access to diagnostic equipment is one of the limiting
factors in efficiently managing this disease. The only reliable and
endorsed technology has been restricted to a few large hospitals.
With the publication of this pivotal study in the scientific renown
journal Osteoporosis International its firmly established that the
Swedish invention can be used for diagnosis of osteoporosis. The
study named “Prevalence of osteoporosis using bone mineral
measurements at the calcaneus by dual X-ray and laser (DXL)” made by
Associate Professor Ragnar Kullenberg, Göteborg University and
Demetech AB and Professor Jan Falch, Center of Endocrinology, Aker
University Hospital, Norway is available online at
www.springer.com
The first product launched based on the DXL technology is DXL
Calscan. It’s a mobile and easy to use instrument, with its superior
accuracy and ease of handling allows diagnosis to be made in primary
care environment. Many more patients can enjoy benefits and receive
proper care as a result, says Anders Reifeldt, President and CEO of
Demetech AB.
Demetech AB is a Swedish company that develops and markets systems
for the diagnosis and early detection of osteoporosis. The company
was founded by Associate Professor Ragnar Kullenberg and Anders
Ullberg, R&D Manager in 1996. The technical development resulted in
the first launch of DXL Calscan in Sweden in 2001 and Europe in
2002. Principal owners are Scandinavian Life Science, Karolinska
Investment Fund, Stena Sessan Rederier AB and the founders. Demetech
is located in Stockholm, Sweden. www.demetech.com
Dual X-ray and
Laser, commonly called DXL, was invented by a team of Swedish
doctors, researchers and engineers. It combines a dual-wavelength
X-ray source with laser definition of the measurement area. The
result is that soft tissue and fatty tissue are excluded from the
bone mineral density reading, resulting in extremely accurate
measurements. DXL offers completely new capabilities for reliable
diagnosis of osteopenia and osteoporosis, long before the first
fracture might occur. The measurements are highly predictive for all
types of brittle bone fractures in the hip, spine wrist and other
bones.
DXL Calscan is the first so called peripheral
instrument based on this technology. DXL Calscan is a portable,
mobile and easy to use diagnostic tool, offering unsurpassed
accuracy and reliability compared to other peripheral instruments.
Anders Reifeldt, President and CEO of Demetech AB.
Phone: +46 8 555 792 00
Mobile: +46 733 10 50 91
E-mail:
anders.reifeldt@demetech.se
You are also welcome to visit
www.demetech.com,
for more information about Demetech AB and the DXL technology.
For more information on Osteoporosis and initiatives to combat the
disease:
www.osteofound.org Osteoporosis International Foundation
www.nof.org
National Osteoporosis Foundation, USA
www.asbmr.org
American Society of Bone and Mineral Research
|
|
